• OUR STATEMENT ON COVID-19
    Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.
    • About Us
    • Pipeline
    • Therapeutic focus
    • Contact us
    • Investors
    Open

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Videos
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
      • Board Diversity Matrix
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Videos
    • Email Alerts
    Nov 12, 2021 8:00am EST

    Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

    Oct 13, 2021 8:00am EDT

    Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

    Oct 05, 2021 8:00am EDT

    Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City

    Sep 22, 2021 4:05pm EDT

    Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

    Sep 13, 2021 8:00am EDT

    Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

    Sep 07, 2021 8:00am EDT

    Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    Aug 12, 2021 8:00am EDT

    Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

    Jun 21, 2021 4:05pm EDT

    Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

    May 06, 2021 8:00pm EDT

    Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering

    • arrow_back
    • 1
    • 2
    • 3
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    Contact

    Anebulo Pharmaceuticals
    1415 Ranch Road 620 South
    Austin, TX 78734
    Phone: 512-598-0931
    Email: info@anebulo.com

    About

    Our Mission
    Management Team
    Board of Directors

    Pipeline

    • ANEB-001
    Anebulo Pharmaceuticals, Inc.
    Facebook Twitter Instagram Reddit
    Back to top

    ©2023 Anebulo Pharmaceuticals. All Rights Reserved.

    Privacy Policy | Terms of Use